Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GH Stock Forecast 2025-2026
$48.30
Current Price
$5.96B
Market Cap
Buy 21
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to GH Price Targets
+34.6%
To High Target of $65.00
+15.9%
To Median Target of $56.00
-2.7%
To Low Target of $47.00
GH Price Momentum
+13.4%
1 Week Change
+12.0%
1 Month Change
+178.4%
1 Year Change
+58.1%
Year-to-Date Change
-5.1%
From 52W High of $50.89
+188.0%
From 52W Low of $16.77
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Guardant Health (GH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GH and similar high-potential opportunities.
Latest GH Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, GH has a bullish consensus with a median price target of $56.00 (ranging from $47.00 to $65.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $48.30, the median forecast implies a 15.9% upside. This outlook is supported by 21 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julia Qin at JP Morgan, projecting a 34.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GH Analyst Ratings
21
Buy
2
Hold
0
Sell
GH Price Target Range
Low
$47.00
Average
$56.00
High
$65.00
Current: $48.30
Latest GH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $55.00 |
| Apr 10, 2025 | Mizuho | Anthony Petrone | Outperform | Initiates | $55.00 |
| Mar 26, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $55.00 |
| Mar 6, 2025 | Morgan Stanley | Shannon O'Callaghan | Overweight | Maintains | $52.00 |
| Feb 26, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $50.00 |
| Feb 24, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $60.00 |
| Feb 24, 2025 | Guggenheim | Subbu Nambi | Buy | Reiterates | $56.00 |
| Feb 24, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $52.00 |
| Feb 21, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $59.00 |
| Feb 21, 2025 | Stifel | Daniel Arias | Buy | Maintains | $53.00 |
| Feb 21, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $56.00 |
| Feb 21, 2025 | JP Morgan | Rachel Vatnsdal | Overweight | Maintains | $55.00 |
| Jan 28, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $49.00 |
| Jan 23, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $60.00 |
| Jan 22, 2025 | Guggenheim | Subbu Nambi | Buy | Reiterates | $0.00 |
| Nov 7, 2024 | JP Morgan | Julia Qin | Overweight | Maintains | $50.00 |
| Nov 7, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $36.00 |
| Oct 30, 2024 | Bernstein | Eve Burstein | Outperform | Maintains | $35.00 |
| Oct 17, 2024 | Leerink Partners | Outperform | Maintains | $50.00 | |
| Aug 21, 2024 | UBS | Dan Leonard | Buy | Maintains | $40.00 |
Guardant Health Inc. (GH) Competitors
The following stocks are similar to Guardant Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
GH
Guardant Health
mkt cap
5.96B
Guardant Health Inc. (GH) Financial Data
Guardant Health Inc. has a market capitalization of $5.96B with a P/E ratio of -13.8x. The company generates $739.02M in trailing twelve-month revenue with a -59.0% profit margin.
Revenue growth is +30.2% quarter-over-quarter, while maintaining an operating margin of -62.8% and return on equity of -4,584.5%.
Valuation Metrics
Market Cap
$5.96B
Enterprise Value
$6.46B
P/E Ratio
-13.8x
PEG Ratio
-17.8x
Price/Sales
8.1x
Growth & Margins
Revenue Growth (YoY)
+30.2%
Gross Margin
+61.6%
Operating Margin
-62.8%
Net Margin
-59.0%
EPS Growth
+30.2%
Financial Health
Cash/Price Ratio
+14.1%
Current Ratio
4.7x
Debt/Equity
-9.6x
ROE
-4,584.5%
ROA
-16.9%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Guardant Health Inc. (GH) Business Model
About Guardant Health Inc.
What They Do
Develops precision oncology diagnostics for cancer detection.
Business Model
Guardant Health generates revenue by providing innovative liquid biopsy technologies that enable non-invasive cancer detection and monitoring. Their offerings are essential for oncologists and researchers, facilitating personalized treatment options and improving patient outcomes.
Additional Information
Founded in 2012 and based in Redwood City, California, Guardant Health is a key player in the biotechnology sector, particularly in precision medicine. The company is focused on expanding its product portfolio and advancing its technologies to enhance early cancer detection and treatment.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,999
CEO
Dr. Helmy Eltoukhy Ph.D.
Country
United States
IPO Year
2018
Website
guardanthealth.comGuardant Health Inc. (GH) Latest News & Analysis
Latest News
Quick Summary
Guardant Health launched Guardant360® Tissue, a comprehensive molecular profiling test for tumor tissue that utilizes multiomics analysis and AI, enhancing cancer research and care capabilities.
Why It Matters
Guardant Health's launch of Guardant360® Tissue enhances cancer diagnostics by integrating multiomics analysis, potentially increasing its market share and attracting investment in precision oncology.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Guardant Health launched Guardant360 Tissue, the first tissue molecular profiling test using comprehensive multiomic analysis for a complete cancer view, powered by its Guardant Infinity platform.
Why It Matters
Guardant Health's launch of a comprehensive tissue molecular profiling test enhances its product offering, potentially boosting revenue and market position in the growing cancer diagnostics sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Guardant Health (GH) is not expected to meet earnings expectations in its upcoming report due to lacking key performance indicators.
Why It Matters
Guardant Health's lack of favorable earnings indicators may signal poor performance, impacting stock price and investor sentiment ahead of the earnings report.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Guardant Health and Pfizer have formed a multi-year collaboration to enhance Pfizer's oncology portfolio using Guardant's Infinity™ liquid biopsy platform for clinical studies.
Why It Matters
The collaboration between Guardant Health and Pfizer enhances Guardant's market position and could drive growth, impacting share prices and investor sentiment in the oncology sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Guardant Health (Nasdaq: GH) will present 18 abstracts, including four oral sessions, on advancements in multi-cancer detection at the AACR Annual Meeting from April 25-30, 2025.
Why It Matters
Guardant Health's presentation at a major cancer research conference highlights its advancements in multi-cancer detection, potentially boosting investor confidence in its growth and innovation.
Source: Business Wire
Market Sentiment:
Neutral
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
11 days ago
Quick Summary
A new oncology advancement may benefit 18 million cancer survivors in the U.S. and strengthen the positions of Guardant Health, Natera, and Exact Sciences.
Why It Matters
Advancements in oncology may increase demand for cancer detection and treatment solutions, positively impacting the stock performance of Guardant Health, Natera, and Exact Sciences.
Source: Investors Business Daily
Market Sentiment:
Positive
Frequently Asked Questions About GH Stock
What is Guardant Health Inc.'s (GH) stock forecast for 2025?
Based on our analysis of 26 Wall Street analysts, Guardant Health Inc. (GH) has a median price target of $56.00. The highest price target is $65.00 and the lowest is $47.00.
Is GH stock a good investment in 2025?
According to current analyst ratings, GH has 21 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $48.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GH stock?
Wall Street analysts predict GH stock could reach $56.00 in the next 12 months. This represents a 15.9% increase from the current price of $48.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Guardant Health Inc.'s business model?
Guardant Health generates revenue by providing innovative liquid biopsy technologies that enable non-invasive cancer detection and monitoring. Their offerings are essential for oncologists and researchers, facilitating personalized treatment options and improving patient outcomes.
What is the highest forecasted price for GH Guardant Health Inc.?
The highest price target for GH is $65.00 from Julia Qin at JP Morgan, which represents a 34.6% increase from the current price of $48.30.
What is the lowest forecasted price for GH Guardant Health Inc.?
The lowest price target for GH is $47.00 from at , which represents a -2.7% decrease from the current price of $48.30.
What is the overall GH consensus from analysts for Guardant Health Inc.?
The overall analyst consensus for GH is bullish. Out of 26 Wall Street analysts, 21 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $56.00.
How accurate are GH stock price projections?
Stock price projections, including those for Guardant Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 4:22 PM UTC